Pricing & Sizes
Ships sealed and lyophilized — stable for years at room temperature, supplied as lyophilised powder. Free shipping on every order, no minimum. Every batch ships with its lab report. Reports come from third-party labs including Janoshik, Freedom Diagnostics and Chromate, most verifiable through the lab's own public portal. Ask and we will send the report for your batch.
Lab report on file. Current batch tested by Freedom Diagnostics — HPLC-UV + MS. Verifiable through the lab's public portal; ask and we will send it.
Reconstitution — bacteriostatic water: 80mg vial reconstituted at 3mL gives 26.7mg/mL. These are concentrations, calculated from vial content and diluent volume. They describe the solution, not a dose.
Bought separately, GHK-Cu 50mg ($35) plus BPC-157 10mg ($48) is $83. KLOW is $110, so 10mg of TB-500 and 10mg of KPV together cost $27. Neither is sold as a standalone vial.
Email To OrderIn Plain English
KLOW bundles four peptides that each target a different part of the repair process: a general repair signal, a tissue-migration signal, an inflammation damper and a copper-carrying skin and collagen peptide. It is the most comprehensive formulation in the range and, for the same reason, the hardest to attribute results to any single component.
What people use it for. The broadest coverage option — repair, inflammation, and skin all in one preparation. People generally choose it when they want one vial to cover several bases rather than running multiple products.
What to know before you buy. The trade-off with four actives is that if something works, or something bothers you, you will have no way of knowing which component did it. If figuring that out matters to you, single compounds answer that question and blends cannot. KLOW also fully overlaps with Wolverine and largely overlaps with GLOW, so these should be alternatives to one another rather than additions.
What It's Studied For
| Research area | What that rests on |
|---|---|
| All-round repair | Four peptides covering repair signalling, inflammation, and skin in one preparation |
| Inflammation | KPV, the anti-inflammatory fragment of α-MSH |
| Skin and collagen | GHK-Cu, the best-evidenced component in the range |
| Simplicity | Replaces running three or four separate products |
The left column lists the research areas this compound is investigated in; the right column states what that rests on. These are published research findings, not proven outcomes or treatment claims, and nothing here is a recommendation. Sold for laboratory research use only.
At a Glance
- Components
- BPC-157, TB-500, KPV, and GHK-Cu
- Typical ratio
- GHK-Cu 50mg / BPC-157 10mg / TB-500 10mg / KPV 10mg
- Rationale
- Repair signalling, anti-inflammatory action and skin or connective tissue support in a single preparation
- Regulatory (US)
- No component is FDA-approved. BPC-157, TB-500 and KPV were each recommended 8-6-1 for 503A listing on 23 July 2026; no FDA action since
- GHK-Cu track
- Not on the July agenda; separate PCAC meeting expected before end of February 2027
- Format
- 80mg vial
Regulatory status
Three components — BPC-157, TB-500 and KPV — were each recommended 8-6-1 for the 503A bulks list on 23 July 2026. That vote is advisory only. As of 17 August 2026 the FDA has taken no action on it, has not opened rulemaking, and has not moved the substance to the interim Category 1 list. FDA’s own scientific reviewers had recommended against all seven peptides; the committee voted against staff on six consecutive votes, so the usual assumption that a PCAC recommendation predicts the agency’s decision is weaker here than normal. GHK-Cu was not reviewed and remains on a separate track expected before the end of February 2027. Several outlets have reported this as the FDA “clearing”, “approving” or “adding” these peptides to the bulks list. That is inaccurate. Nothing has been added and nothing is legally cleared.
How the Components Compare
| Component | What it adds | What it does not do |
|---|---|---|
| GHK-Cu | Best-evidenced of the four. Collagen, skin firmness, hair — the cosmetic layer none of the others cover | Evidence is largely topical. No anti-inflammatory or tendon-specific role |
| BPC-157 | Broad repair signalling plus the gut application unique to it in this blend | Nothing for skin or collagen. No completed human trial |
| TB-500 | Cell migration and tissue remodelling — a different repair route from BPC-157 | No direct research of its own. No skin or inflammation role |
| KPV | The only anti-inflammatory in the blend, and the only component with no identity ambiguity at all | Does not drive tissue repair or collagen synthesis. No completed human trial |
Component Breakdown
| Component | Role in the formulation | July 2026 PCAC |
|---|---|---|
| GHK-Cu | Collagen synthesis, skin remodelling, antioxidant activity | Not reviewed — Feb 2027 track |
| BPC-157 | Broad tissue repair signalling | Recommended 8-6-1 |
| TB-500 | Cell migration and tissue repair, inferred from Tβ4 | Recommended 8-6-1 |
| KPV | Anti-inflammatory; C-terminal fragment of α-MSH | Recommended 8-6-1 |
Practical Considerations
Attribution
With four actives in one vial there is no clean way to tell which component is producing an effect, or which is producing an unwanted one. If isolating a variable matters to you, a single-component preparation answers that question and a four-way blend cannot.
Overlap
KLOW contains both BPC-157 and TB-500, so it overlaps completely with Wolverine and substantially with GLOW. Running KLOW alongside either one compounds those doses rather than broadening coverage. Replacing rather than stacking is the cleaner approach.
The bottom line
The most complete formulation in the range, and the one with the most split regulatory picture — three components carrying a July 2026 recommendation the FDA has not acted on, and one that has not been reviewed at all. Comprehensive by design.